The tumour suppressor OPCML promotes AXL inactivation by the phosphatase PTPRG in ovarian cancer

Jane Antony, Elisa Zanini, Zoe Kelly, Tuan Zea Tan, Evdoxia Karali, Mohammad Alomary, Youngrock Jung, Katherine Nixon, Paula Cunnea, Christina Fotopoulou, Andrew Paterson, Sushmita Roy-Nawathe, Gordon Mills, Ruby Yun Ju Huang, Jean Paul Thiery, Hani Gabra, Chiara Recchi

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

In ovarian cancer, the prometastatic RTK AXL promotes motility, invasion and poor prognosis. Here, we show that reduced survival caused by AXL overexpression can be mitigated by the expression of the GPI-anchored tumour suppressor OPCML. Further, we demonstrate that AXL directly interacts with OPCML, preferentially so when AXL is activated by its ligand Gas6. As a consequence, AXL accumulates in cholesterol-rich lipid domains, where OPCML resides. Here, phospho-AXL is brought in proximity to the lipid domain-restricted phosphatase PTPRG, which de-phosphorylates the RTK/ligand complex. This prevents AXL-mediated transactivation of other RTKs (cMET and EGFR), thereby inhibiting sustained phospho-ERK signalling, induction of the EMT transcription factor Slug, cell migration and invasion. From a translational perspective, we show that OPCML enhances the effect of the phase II AXL inhibitor R428 in vitro and in vivo. We therefore identify a novel mechanism by which two spatially restricted tumour suppressors, OPCML and PTPRG, coordinate to repress AXL-dependent oncogenic signalling.

Original languageEnglish (US)
Article numbere45670
JournalEMBO Reports
Volume19
Issue number8
DOIs
StatePublished - Aug 1 2018
Externally publishedYes

Fingerprint

Class 5 Receptor-Like Protein Tyrosine Phosphatases
Ovarian Neoplasms
Tumors
Ligands
Lipids
Transcriptional Activation
Cell Movement
Neoplasms
Transcription Factors
Cholesterol

Keywords

  • AXL
  • OPCML
  • ovarian cancer
  • PTPRG

ASJC Scopus subject areas

  • Biochemistry
  • Molecular Biology
  • Genetics

Cite this

Antony, J., Zanini, E., Kelly, Z., Tan, T. Z., Karali, E., Alomary, M., ... Recchi, C. (2018). The tumour suppressor OPCML promotes AXL inactivation by the phosphatase PTPRG in ovarian cancer. EMBO Reports, 19(8), [e45670]. https://doi.org/10.15252/embr.201745670

The tumour suppressor OPCML promotes AXL inactivation by the phosphatase PTPRG in ovarian cancer. / Antony, Jane; Zanini, Elisa; Kelly, Zoe; Tan, Tuan Zea; Karali, Evdoxia; Alomary, Mohammad; Jung, Youngrock; Nixon, Katherine; Cunnea, Paula; Fotopoulou, Christina; Paterson, Andrew; Roy-Nawathe, Sushmita; Mills, Gordon; Huang, Ruby Yun Ju; Thiery, Jean Paul; Gabra, Hani; Recchi, Chiara.

In: EMBO Reports, Vol. 19, No. 8, e45670, 01.08.2018.

Research output: Contribution to journalArticle

Antony, J, Zanini, E, Kelly, Z, Tan, TZ, Karali, E, Alomary, M, Jung, Y, Nixon, K, Cunnea, P, Fotopoulou, C, Paterson, A, Roy-Nawathe, S, Mills, G, Huang, RYJ, Thiery, JP, Gabra, H & Recchi, C 2018, 'The tumour suppressor OPCML promotes AXL inactivation by the phosphatase PTPRG in ovarian cancer', EMBO Reports, vol. 19, no. 8, e45670. https://doi.org/10.15252/embr.201745670
Antony, Jane ; Zanini, Elisa ; Kelly, Zoe ; Tan, Tuan Zea ; Karali, Evdoxia ; Alomary, Mohammad ; Jung, Youngrock ; Nixon, Katherine ; Cunnea, Paula ; Fotopoulou, Christina ; Paterson, Andrew ; Roy-Nawathe, Sushmita ; Mills, Gordon ; Huang, Ruby Yun Ju ; Thiery, Jean Paul ; Gabra, Hani ; Recchi, Chiara. / The tumour suppressor OPCML promotes AXL inactivation by the phosphatase PTPRG in ovarian cancer. In: EMBO Reports. 2018 ; Vol. 19, No. 8.
@article{32560978d9354ec99d4150ed1f13e8fc,
title = "The tumour suppressor OPCML promotes AXL inactivation by the phosphatase PTPRG in ovarian cancer",
abstract = "In ovarian cancer, the prometastatic RTK AXL promotes motility, invasion and poor prognosis. Here, we show that reduced survival caused by AXL overexpression can be mitigated by the expression of the GPI-anchored tumour suppressor OPCML. Further, we demonstrate that AXL directly interacts with OPCML, preferentially so when AXL is activated by its ligand Gas6. As a consequence, AXL accumulates in cholesterol-rich lipid domains, where OPCML resides. Here, phospho-AXL is brought in proximity to the lipid domain-restricted phosphatase PTPRG, which de-phosphorylates the RTK/ligand complex. This prevents AXL-mediated transactivation of other RTKs (cMET and EGFR), thereby inhibiting sustained phospho-ERK signalling, induction of the EMT transcription factor Slug, cell migration and invasion. From a translational perspective, we show that OPCML enhances the effect of the phase II AXL inhibitor R428 in vitro and in vivo. We therefore identify a novel mechanism by which two spatially restricted tumour suppressors, OPCML and PTPRG, coordinate to repress AXL-dependent oncogenic signalling.",
keywords = "AXL, OPCML, ovarian cancer, PTPRG",
author = "Jane Antony and Elisa Zanini and Zoe Kelly and Tan, {Tuan Zea} and Evdoxia Karali and Mohammad Alomary and Youngrock Jung and Katherine Nixon and Paula Cunnea and Christina Fotopoulou and Andrew Paterson and Sushmita Roy-Nawathe and Gordon Mills and Huang, {Ruby Yun Ju} and Thiery, {Jean Paul} and Hani Gabra and Chiara Recchi",
year = "2018",
month = "8",
day = "1",
doi = "10.15252/embr.201745670",
language = "English (US)",
volume = "19",
journal = "EMBO Reports",
issn = "1469-221X",
publisher = "Nature Publishing Group",
number = "8",

}

TY - JOUR

T1 - The tumour suppressor OPCML promotes AXL inactivation by the phosphatase PTPRG in ovarian cancer

AU - Antony, Jane

AU - Zanini, Elisa

AU - Kelly, Zoe

AU - Tan, Tuan Zea

AU - Karali, Evdoxia

AU - Alomary, Mohammad

AU - Jung, Youngrock

AU - Nixon, Katherine

AU - Cunnea, Paula

AU - Fotopoulou, Christina

AU - Paterson, Andrew

AU - Roy-Nawathe, Sushmita

AU - Mills, Gordon

AU - Huang, Ruby Yun Ju

AU - Thiery, Jean Paul

AU - Gabra, Hani

AU - Recchi, Chiara

PY - 2018/8/1

Y1 - 2018/8/1

N2 - In ovarian cancer, the prometastatic RTK AXL promotes motility, invasion and poor prognosis. Here, we show that reduced survival caused by AXL overexpression can be mitigated by the expression of the GPI-anchored tumour suppressor OPCML. Further, we demonstrate that AXL directly interacts with OPCML, preferentially so when AXL is activated by its ligand Gas6. As a consequence, AXL accumulates in cholesterol-rich lipid domains, where OPCML resides. Here, phospho-AXL is brought in proximity to the lipid domain-restricted phosphatase PTPRG, which de-phosphorylates the RTK/ligand complex. This prevents AXL-mediated transactivation of other RTKs (cMET and EGFR), thereby inhibiting sustained phospho-ERK signalling, induction of the EMT transcription factor Slug, cell migration and invasion. From a translational perspective, we show that OPCML enhances the effect of the phase II AXL inhibitor R428 in vitro and in vivo. We therefore identify a novel mechanism by which two spatially restricted tumour suppressors, OPCML and PTPRG, coordinate to repress AXL-dependent oncogenic signalling.

AB - In ovarian cancer, the prometastatic RTK AXL promotes motility, invasion and poor prognosis. Here, we show that reduced survival caused by AXL overexpression can be mitigated by the expression of the GPI-anchored tumour suppressor OPCML. Further, we demonstrate that AXL directly interacts with OPCML, preferentially so when AXL is activated by its ligand Gas6. As a consequence, AXL accumulates in cholesterol-rich lipid domains, where OPCML resides. Here, phospho-AXL is brought in proximity to the lipid domain-restricted phosphatase PTPRG, which de-phosphorylates the RTK/ligand complex. This prevents AXL-mediated transactivation of other RTKs (cMET and EGFR), thereby inhibiting sustained phospho-ERK signalling, induction of the EMT transcription factor Slug, cell migration and invasion. From a translational perspective, we show that OPCML enhances the effect of the phase II AXL inhibitor R428 in vitro and in vivo. We therefore identify a novel mechanism by which two spatially restricted tumour suppressors, OPCML and PTPRG, coordinate to repress AXL-dependent oncogenic signalling.

KW - AXL

KW - OPCML

KW - ovarian cancer

KW - PTPRG

UR - http://www.scopus.com/inward/record.url?scp=85051058060&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85051058060&partnerID=8YFLogxK

U2 - 10.15252/embr.201745670

DO - 10.15252/embr.201745670

M3 - Article

VL - 19

JO - EMBO Reports

JF - EMBO Reports

SN - 1469-221X

IS - 8

M1 - e45670

ER -